Sareum Holdings PLC
25 July 2005
For immediate release 25 July 2005
SAREUM HOLDINGS PLC, THE INSTITUTE OF CANCER RESEARCH AND CANCER RESEARCH
TECHNOLOGY LTD
Major Cancer Drug Discovery Collaboration
Sareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug
discovery and services business, The Institute of Cancer Research (The
Institute), Europe's leading cancer research centre, and Cancer Research
Technology Limited (CRT), the oncology focused development and commercialisation
company, are pleased to announce that they have entered into a joint
collaboration to develop novel cancer therapeutics.
The collaboration will establish a joint research team to target a biochemical
pathway, responsible for resistance to the effectiveness of traditional cancer
therapeutics, found in more than half of solid tumour types. The team will work
towards developing cancer treatments with valuable benefits for cancer patients
including lower doses of existing therapies, fewer adverse side-effects and
efficacy where tumours currently do not respond to chemotherapy.
Sareum will use its expertise in high-throughput protein expression, structure
determination computational and medicinal chemistry to identify novel compounds
using its innovative Template Screening technology. Combining Sareum's
experience with the vast expertise in drug development at The Cancer Research UK
Centre for Cancer Therapeutics at The Institute of Cancer Research, this joint
collaboration plans to rapidly develop such compounds into more effective cancer
therapies.
Under the terms of the agreement, drug candidates developed by the collaboration
are intended to be licensed by CRT to pharmaceutical partners for clinical
trials. Payments, milestones and royalties arising from any partnering deals
will be shared between Sareum, The Institute and CRT.
Commenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell,
said: "I am delighted that we have entered into this major collaboration with
such prestigious partners in the field of cancer. The collaboration with The
Institute of Cancer Research and Cancer Research Technology has huge potential
in the field of cancer drug discovery and I look forward to taking novel cancer
therapies developed in this collaboration to the clinic."
Professor Paul Workman, Director of The Cancer Research UK Centre for Cancer
Therapeutics at The Institute of Cancer Research, said: "These are very exciting
times in cancer drug development. This collaboration will bring together many
years of expertise and experience in targeting cancer, which we hope will
ultimately allow us to use existing drugs more effectively and hence improve
cancer management."
Dr Keith Blundy, COO of Cancer Research Technology Limited said: "This
partnership further exemplifies CRT's role in bringing benefit to cancer
patients by forming partnerships between cancer researchers and industry to
accelerate the development of new therapies. Sareum's technologies and the
expertise of ICR will add significantly to the rate of progress of the
programme."
For further information:
Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer
The Institute of Cancer Research 020 7153 5359
Nadia Ramsey, Science Press Officer
Cancer Research UK 020 7242 0200
Sophy Gould, Senior Press Officer
Cancer Research Technology Limited 0207 679 3640
Nick Wells, Marketing and Business Manager
Buchanan Communications 020 7466 5000
Mark Court, Mary-Jane Johnson
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a specialist structure based drug discovery business
headquartered in Cambridge, UK. The Company was formed in August 2003 to
discover new drugs for the treatment of cancer and to provide a range of drug
discovery services to the pharmaceutical industry. Sareum's unique approach aims
to halve the time it takes to discover new drug candidates.
Structure-based drug discovery involves the determination of a disease causing
protein's three-dimensional structure. Once the structure is known, novel
chemical entities are designed to 'lock-in' to the protein with the aim of
reversing or arresting a disease's progression.
Sareum's approach to structure based drug discovery is to produce multiple
recombinant proteins primarily through a baculovirus expression system;
determine their structure using x-ray crystallography; and then use the
Company's template-molecule x-ray screening technology to identify new chemical
entities that interact with the target protein. Sareum then uses its
high-throughput medicinal chemistry platform to rapidly synthesise further
molecules and develop the most promising into potential drug candidates.
Sareum offers its accelerated drug discovery capabilities on a fee basis to the
pharmaceutical and biotechnology industries. Sareum intends to license out its
internally generated drug candidates at the Phase I or Phase II clinical trials
stage.
Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk
About The Institute of Cancer Research
The Institute of Cancer Research is Europe's leading cancer research centre with
expert scientists working on cutting edge research. It was founded in 1909 to
carry out research into the causes of cancer and to develop new strategies for
its prevention, diagnosis, treatment and care. For more information please visit
www.icr.ac.uk
The Institute works in a unique partnership with the Royal Marsden NHS
Foundation Trust, forming the largest comprehensive cancer centre in Europe. The
Institute is unrivalled in its record in cancer drug discovery and development.
The Institute is a charity that relies on voluntary income. The Institute is a
highly cost-effective major cancer research organisation with over 90p in every
£ directly supporting research.
About Cancer Research Technology Limited
Cancer Research Technology Limited (CRT) is a specialist technology transfer and
development company which aims to develop new discoveries in cancer research for
the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the
largest independent funder of cancer research in the world. CRT works closely
with leading international cancer scientists and their institutes to protect
intellectual property arising from their research and to establish links with
commercial partners. CRT facilitates the discovery, development and marketing of
new cancer therapeutics, vaccines, diagnostics and enabling technologies.
Further information about CRT can be found at www.cancertechnology.com.
Cancer Research UK is the world's leading charity dedicated to research on the
causes, treatment and prevention of cancer. The charity supports the work of
3,000 scientists, doctors and nurses in over 80 academic centres across the UK,
with an annual scientific spend of more than £213 million. Further information
about Cancer Research UK can be found at www.cancerresearchuk.org.
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.